Product Description
For dyslipidemia and Type II Diabetes
Mechanisms of Action: AMPK Binder,HMG-CoA Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Yuhan
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Dyslipidemia|Type 2 Diabetes
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
YH14755-301 | P3 |
Completed |
Type 2 Diabetes|Dyslipidemia |
2017-07-07 |
60% |
YH14755-102 | P1 |
Completed |
Healthy Volunteers |
2014-09-01 |